Bernadette Connaughton Sells 1,625 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25. Following the sale, the director directly owned 43,669 shares of the company’s stock, valued at $2,891,324.49. This represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

• On Friday, May 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00.

Halozyme Therapeutics Price Performance

HALO stock opened at $69.82 on Thursday. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a one year low of $51.06 and a one year high of $82.22. The firm has a market capitalization of $8.28 billion, a PE ratio of 25.12, a P/E/G ratio of 0.27 and a beta of 0.88. The firm has a 50-day moving average of $66.44 and a two-hundred day moving average of $68.71.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s quarterly revenue was up 42.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 7.6 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on HALO shares. UBS Group reissued a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday. HC Wainwright increased their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $81.60.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alpine Woods Capital Investors LLC bought a new position in Halozyme Therapeutics during the first quarter valued at approximately $281,000. Glenmede Trust Co. NA raised its position in Halozyme Therapeutics by 22.4% during the first quarter. Glenmede Trust Co. NA now owns 146,717 shares of the biopharmaceutical company’s stock valued at $9,482,000 after acquiring an additional 26,851 shares in the last quarter. Argent Capital Management LLC raised its position in Halozyme Therapeutics by 52.2% during the first quarter. Argent Capital Management LLC now owns 9,054 shares of the biopharmaceutical company’s stock valued at $585,000 after acquiring an additional 3,104 shares in the last quarter. BankChampaign National Association bought a new position in Halozyme Therapeutics during the first quarter valued at approximately $228,000. Finally, Western Wealth Management LLC bought a new position in Halozyme Therapeutics during the first quarter valued at approximately $229,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.